

Index

A

- Acquired pseudogenes, 119–120
- Adenocarcinoma, 58
- Aging, 177–195
 - aging-related metabolic pathways, 182–184
 - molecular damage, 179–182
 - noncoding RNAs in, 184–186
 - noncoding transcriptional landscape in, 177–195
 - pathways, 179–184
 - regulatory lncRNAs as modulators of, 186–194
 - DNA damage, 187–190
 - functional features, 186–187
 - and inflammation, 191–192
 - insulin pathway and, 193
 - in mTOR pathway, 193–194
 - in sirtuin pathways, 193–194
 - in WNT pathway, 193–194
- Aneuploidy, 12
- ANRIL (Antisense non-coding RNA in the INK4 locus), 29–36
 - and cancer predisposition, 34–36
 - circular ANRIL (cANRIL), 31
 - and polycomb group proteins, 31–32
- Autophagy, 182

B

- Bacterial stress response, lncRNAs in, 208–209
 - CRISPR RNAs, 209
 - CsrB, 209
 - 6S RNAs, 209
 - sRNAs, 209
- Biomarkers, 58, 249, 253
- Blaschko's lines, 18

C

- CAGE, 239, 241–245, 249, 253
- Cancer, 58

- predisposition, ANRIL and, 34–36
 - X-inactivation and, 13–16
- Cardiovascular diseases (CVDs), 129–130
- Chr9p21 loci, 30–31
 - DNA landscape overlapping, 30–31
 - RNA landscape overlapping, 30–31
- Coactivator, 145
- Corepressor, 145

D

- DNA methyltransferase 3a (DNMT3a), 43
- Down syndrome, 13, 18
- DXPas34, 9–10

E

- Edwards syndrome, 13
- Enhancer of zeste homolog 2 (EZH2), 43
- Enhancer RNAs, 243, 244, 249
- ER stress, 223
- Escape genes, 13
- Eukaryotic stress response, lncRNAs in, 210–215
- Exfoliation syndrome (XFS), 216
- Exosomes, 41, 45–52
 - exosome-mediated delivery of lncRNAs, 48
 - and lncRNAs, 51
- Expression specificity, 241, 243, 252, 253

F

- FANTOM, 241–245, 249, 252, 253
- Five Prime to Xist (Ftx), 11

G

- Genotoxic stress, lncRNAs in, 216–218

H

- Heat shock-induced lncRNAs, 221–222
- Heat shock proteins (HSP), 218–220
- Heat stress, lncRNAs in, 218–221

- HIF-induced lncRNAs, 211–213
- HMGAI pseudogene, 118
- Hormone associated cancer, 159–162
- HOTAIR lncRNA, 44, 51, 66–67, 192
- HOX transcript antisense RNA (HOTAIR), 44, 51
- Human induced pluripotent stem cells (hiPSCs), 15
- Hypoxia-induced histone deacetylase 3 (HDAC3), 214
- Hypoxic stress, lncRNAs in, 210–215
 - HIF-induced lncRNAs role, 211–213
 - hypoxia-induced epigenetic changes, 213–215
- I**
- Incontinentia pigmenti, 18
- Inflammation, lncRNAs and, 191–192
- K**
- KRAS, 49
- L**
- Long intergenic radiation-responsive ncRNAs (LIRRs), 188
- Long interspersed elements (LINE), 119
- Long non-coding RNAs (lncRNAs), 41–46, 48, 51, 52, 59, 130–132, 143, 144. *See also* Regulatory lncRNAs
- ANRIL, 62. *See also separate entry*
- BANCR, 62
- BC200, 63
- CARLO-5, 62
- CCAT1, 77
- CCAT1-L, 77
- CCAT2, 62
- complex circuitry, at X-inactivation center, 1–20
- CUDR, 63
- GAS5, 62
- GAS6-AS1, 62
- genomic origins of, 208
- GHSROS, 62
- H19, 62
- HOTAIR, 44, 62, 66–67
- lncRNA-LET, 63
- MALAT1, 62
- MEG3, 62
- molecular roles of, 130
- MVIH, 62
- negative lncRNA regulators of Xist, 8–10
 - DXPas34, 9–10
 - testes-specific X-linked noncoding RNA (Tsx), 10
 - Tsix, 8–9
 - Xite, 9–10
- positive lncRNA regulators of Xist, 10–12
 - Jpx/Enox, 10–11
 - RepA, 11–12
- PVT1, 62
- SCAL1, 62
- SOX2OT, 62
- SPRY4-IT1, 62
- in stress response, 203–225. *See also under* Stress response
- TUG1, 62
- in VSMCs, 132–136
 - humans, 134
 - rats, 133
- on Xic, 6
- in Xist expression control, 8–12
- ZXF1, 63
- Lung cancer, 58
- M**
- Marker, 64
- Membranous nephropathy (MN), 19
- Metabolic pathways, aging-related, 182–184
- Metastasis, 58
- Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), 44, 45, 51
- Methyl-CpG binding protein 2 (MECP2), 17
- Methyl-thioadenosine phosphorylase (MTAP), 29
- MicroRNAs (miRNAs), 128–129, 144
- mTOR pathway, regulatory lncRNAs in, 193–194
- Myeloproliferative/myelodysplastic syndrome [MPN/MDS], 15
- N**
- Negative lncRNA regulators of Xist, 8–10
- NFkB essential modulator (NEMO), 18
- Non-coding RNAs, 129–132, 242, 250
 - in aging, 184–186
 - long non-coding RNAs (lncRNAs), 130–132
- Noncoding transcriptional landscape in aging, 177–195. *See also* Aging
- Non-small cell lung cancer (NSCLC), 58
- Nuclear receptors (NRs), 143, 145
 - androgen receptor AR, 145
 - estrogen receptors ERs, 145
 - glucocorticoid receptor GR, 145

- mineralocorticoid receptor MR, 145
 - progesterone receptor PR, 145
 - retinoic acid (RARs), 145
 - thyroid hormone (TRs), 145
 - vitamin D (VDR), 145
- O**
- OCT4 pseudogenes, 115
 - Osmotic stress, 223
 - Oxidative stress, lncRNAs in, 215–216
- P**
- Patau syndrome, 13
 - Personalized medicine, 252, 254
 - Phosphatase and tensin homolog (PTEN), 43, 48, 50
 - Plants, stress in, lncRNAs and, 224
 - Polycomb group (PcG) in human diseases, 29–36
 - ANRIL and, 31–32
 - Positive lncRNA regulators of Xist, 10–12
 - Ftx (Five Prime to Xist), 11
 - Jpx/Enox, 10–11
 - RepA, 11–12
 - Processed pseudogenes, 113
 - Proteostasis, 181
 - Pseudogene-expressed RNAs, 111–122
 - in gene disease, 111–122
 - in gene regulation, 111–122
 - Pseudogenes, 43, 113–121
 - acquired pseudogenes, 119–120
 - in cancer tissues, 114–115
 - HMG A1 pseudogene, 118
 - mediated regulation, 116
 - OCT4, 115
 - processed, 113
 - in pro-inflammatory signaling, 119
 - pseudogene-encoded asRNAs, 120
 - PTEN pseudogene, 117
 - unitary, 113–114
 - unprocessed, 113
 - Pseudogenization, 113
 - PTENpg1, 43, 117
 - PTENpg1 sense/antisense, 43
 - PTEN-targeted miRNAs, 43
- R**
- Regulatory lncRNAs
 - DNA damage and, 187–190
 - inflammation and, 191–192
 - insulin pathway and, 193
 - as modulators of aging, 186–194
 - in mTOR pathway, 193–194
 - senescence regulation by, 192
 - in sirtuin pathways, 193–194
 - within aging transcriptional landscape, 186–187
 - in WNT pathway, 193–194
 - Repetitive elements, 241, 242, 245, 248, 249
 - Rett syndrome, 16
 - RNA polymerase II (Pol II), 144
 - RNA-mediated regulation in stress response, 207–208
- S**
- Senescence regulation by lncRNAs, 192
 - Sirtuin pathway, regulatory lncRNAs in, 193–194
 - Skewed X-inactivation, 16–18
 - Small cell lung cancer (SCLC), 58
 - Squamous cell carcinoma, 58
 - Starvation, 223
 - Stress response, lncRNAs in, 203–225
 - bacterial stress response, 208–209
 - ER stress, 223
 - eukaryotic stress response, 210–215
 - genotoxic stress, 216–218
 - heat shock-induced lncRNAs, 221–222
 - heat stress, 218–221
 - hypoxic stress, 210–215
 - osmotic stress, 223
 - oxidative stress, 215–216
 - RNA-mediated regulation, 207–208
 - starvation, 223
 - stress in plants, 224
- T**
- TERRA (Telomeric Repeat containing RNAs), 45
 - Testes-specific X-linked noncoding RNA (Tsx), 10
 - Testicular germ cell tumors (TGCTs), 19
 - Therapeutic targets, 240, 249
 - Thoracic aortic aneurysms (TAA), 135
 - Transcription factors (TFs), 145
 - Tsix, 8–9
- U**
- Unitary pseudogenes, 113–114
 - Unprocessed pseudogenes, 113
 - Urothelial cancer-associated 1 (UCA1), 212
- V**
- Vascular smooth muscle cells (VSMCs), 127–137
 - lncRNAs in, 132–136

W

WNT pathway, regulatory lncRNAs in,
193–194

X

X chromosome inactivation (X-inactivation),
3–5

X-inactivation and disease, 12–18
cancer, 13–16
diagnostic applications, 18–19
Down syndrome, 13
Edwards syndrome, 13

incontinentia pigmenti, 18

Patau syndrome, 13

Rett syndrome, 16

skewed X-inactivation, 16–18

therapeutic applications, 18–19

X-inactivation center (Xic), 1–20
lncRNAs at, 1–20

X-inactivation Intergenic Transcription (Xite),
9–10

X-inactive specific transcript (Xist), 7–8

negative lncRNA regulators of, 8–10

positive lncRNA regulators of Xist, 10–12